Four-Drug cocktail aims to control myeloma without transplant
NCT ID NCT07663253
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd)—in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see how well the regimen controls the disease and what side effects occur in real-world practice. Participants receive the drugs in cycles over about eight months, followed by possible maintenance therapy. The study will measure response rates, including how deeply the cancer is suppressed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab (Sarclisa) combined with bortezomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this combination could offer a powerful, chemotherapy-free option to control multiple myeloma in people who cannot undergo a stem cell transplant.
What could go wrong
This is an observational study without a comparison group, so results may be less definitive. Side effects from the drug combination can be serious, including infections and blood count changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Nantong University
RECRUITINGNantong, Jiangsu, China
Contact Email: •••••@•••••
-
Fudan University Affiliated Zhongshan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Institute of Hematologic Oncology
RECRUITINGHarbin, Heilongjiang, China
Contact Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Contact Email: •••••@•••••
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Email: •••••@•••••
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••
-
Shenzhen People's Hospital
RECRUITINGShenzhen, Guangdong, China
Contact Email: •••••@•••••
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, China
Contact Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNaning, Guangxi, 450000, China
Contact Email: •••••@•••••
-
The First Affiliated Hospital of Kunming Medical University
RECRUITINGKunming, Yunnan, China
Contact Email: •••••@•••••
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
RECRUITINGWuhan, Hubei, China
Contact Email: •••••@•••••
-
Xijing Hospital, Air Force Medical University
RECRUITINGXi’an, Shanxi, China
Contact Email: •••••@•••••